Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

MorphoSys AG. (8/1/18). "Press Release: MorphoSys AG Reports Second Quarter 2018 Financial Results". Planegg.

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
  Organisation 2 Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
Products Product tafasitamab (MOR208 / XmAb5574)
  Product 2 Tremfya™
Index term Index term MorphoSys–SEVERAL: investment, 201803–201804 US IPO $208m+$31m with 8.3m+1.245m ADSs at $25.04/ADS + listing at Nasdaq Global Market
Persons Person Moroney, Simon E. (MorphoSys 1992–201908 CEO + Founder STEPPED DOWN 9/19)
  Person 2 Herron, Jennifer (ADC Therapeutics 201911– CCO based in US before Immunogen + MorphoSys US + Ariad + BMS)
     


   
Record changed: 2018-08-11

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px




» top